

Vincenzo Cerullo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9527628/publications.pdf>

Version: 2024-02-01

137
papers

5,331
citations

81900

39
h-index

98798

67
g-index

149
all docs

149
docs citations

149
times ranked

5213
citing authors

#	ARTICLE	IF	CITATIONS
1	Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptorâ€“Modified T Cells in Solid Tumors. <i>Cancer Research</i> , 2014, 74, 5195-5205.	0.9	269
2	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. <i>Molecular Therapy</i> , 2010, 18, 1874-1884.	8.2	201
3	Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. <i>Cancer Research</i> , 2010, 70, 4297-4309.	0.9	197
4	Ischemic Neoangiogenesis Enhanced by β_2 -Adrenergic Receptor Overexpression. <i>Circulation Research</i> , 2005, 97, 1182-1189.	4.5	154
5	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSFâ€“Coding Oncolytic Adenovirus. <i>Clinical Cancer Research</i> , 2013, 19, 2734-2744.	7.0	150
6	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. <i>Molecular Therapy</i> , 2013, 21, 1212-1223.	8.2	146
7	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. <i>Cancer Research</i> , 2012, 72, 2327-2338.	0.9	144
8	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1737-1746.	8.2	141
9	Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. <i>Gene Therapy</i> , 2012, 19, 988-998.	4.5	132
10	Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors. <i>Molecular Therapy</i> , 2007, 15, 378-385.	8.2	130
11	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. <i>Cancer Research</i> , 2012, 72, 1621-1631.	0.9	117
12	PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. <i>Gene Therapy</i> , 2005, 12, 579-587.	4.5	115
13	Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. <i>Journal of Cell Biology</i> , 2008, 181, 803-816.	5.2	106
14	Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 3035-3043.	7.0	97
15	Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. <i>Journal of Controlled Release</i> , 2018, 283, 223-234.	9.9	95
16	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. <i>Journal of Controlled Release</i> , 2019, 294, 165-175.	9.9	93
17	AKT Participates in Endothelial Dysfunction in Hypertension. <i>Circulation</i> , 2004, 109, 2587-2593.	1.6	89
18	Artificially cloaked viral nanovaccine for cancer immunotherapy. <i>Nature Communications</i> , 2019, 10, 5747.	12.8	86

#	ARTICLE	IF	CITATIONS
19	An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance. <i>Molecular Therapy</i> , 2012, 20, 2076-2086.	8.2	84
20	Design and application of oncolytic viruses for cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 25-36.	6.6	84
21	Integrin targeted oncolytic adenoviruses Ad5â€”RGD and Ad5â€”RGDâ€”GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. <i>International Journal of Cancer</i> , 2012, 130, 1937-1947.	5.1	82
22	Oncolytic vaccinia virus for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 595-608.	3.1	78
23	Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. <i>Oncology</i> , 2016, 5, e1105429.	4.6	70
24	Genetic diversity and tumor immunosurveillance. <i>Journal of Thoracic Disease</i> , 2013, 5, 6-7.	1.4	66
25	Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. <i>Molecular Therapy</i> , 2012, 20, 1821-1830.	8.2	64
26	Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. <i>Gene Therapy</i> , 2010, 17, 892-904.	4.5	61
27	Oncolytic Adenoviruses for Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2012, 115, 265-318.	5.0	61
28	Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects. <i>Current Gene Therapy</i> , 2007, 7, 297-305.	2.0	60
29	Oncolytic Viruses for Induction of Anti-Tumor Immunity. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1750-1760.	1.6	56
30	The Evolution of Adenoviral Vectors through Genetic and Chemical Surface Modifications. <i>Viruses</i> , 2014, 6, 832-855.	3.3	53
31	Oncolytic adenovirus based on serotype 3. <i>Cancer Gene Therapy</i> , 2011, 18, 288-296.	4.6	51
32	Oncolytic adenovirus and doxorubicinâ€”based chemotherapy results in synergistic antitumor activity against softâ€”tissue sarcoma. <i>International Journal of Cancer</i> , 2015, 136, 945-954.	5.1	51
33	Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models. <i>Journal of Virology</i> , 2010, 84, 856-866.	3.4	50
34	Generation of Helper-Dependent Adenoviral Vectors by Homologous Recombination. <i>Molecular Therapy</i> , 2002, 5, 204-210.	8.2	49
35	Synergistic antiâ€”tumor efficacy of immunogenic adenovirus ONCOSâ€”102 (Ad5/3â€”GMâ€”CSF) and standard of care chemotherapy in preclinical mesothelioma model. <i>International Journal of Cancer</i> , 2016, 139, 1883-1893.	5.1	46
36	Patient-Derived Organoids for Precision Cancer Immunotherapy. <i>Cancer Research</i> , 2021, 81, 3149-3155.	0.9	46

#	ARTICLE	IF	CITATIONS
37	Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral Vectors. <i>Molecular Therapy</i> , 2007, 15, 2080-2087.	8.2	45
38	Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1858-1866.	8.2	42
39	Immunological Effects of a Tumor Necrosis Factor Alpha-armed Oncolytic Adenovirus. <i>Human Gene Therapy</i> , 2015, 26, 134-144.	2.7	42
40	Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction. <i>Nanoscale</i> , 2020, 12, 2350-2358.	5.6	42
41	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. <i>International Journal of Cancer</i> , 2015, 137, 1775-1783.	5.1	41
42	Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 651-660.	4.1	41
43	Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. <i>Molecular Therapy</i> , 2018, 26, 2315-2325.	8.2	41
44	Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. <i>Cancer Research</i> , 2020, 80, 2575-2585.	0.9	39
45	Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. <i>Clinical Cancer Research</i> , 2010, 16, 2540-2549.	7.0	37
46	Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. <i>Journal of Gene Medicine</i> , 2010, 12, 435-445.	2.8	36
47	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. <i>International Journal of Cancer</i> , 2014, 135, 720-730.	5.1	36
48	Antitumor-specific T cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3- Δ 24-GM-CSF) in peritoneal mesothelioma mouse model. <i>Journal of Medical Virology</i> , 2018, 90, 1669-1673.	5.0	36
49	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. <i>ACS Nano</i> , 2019, 13, 6477-6490.	14.6	36
50	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment. <i>PLoS ONE</i> , 2017, 12, e0182715.	2.5	34
51	Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system. <i>Chemical Communications</i> , 2012, 48, 9310.	4.1	33
52	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. <i>Acta Oncologica</i> , 2010, 49, 120-122.	1.8	32
53	CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. <i>Gene Therapy</i> , 2014, 21, 195-204.	4.5	32
54	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16002.	4.4	32

#	ARTICLE	IF	CITATIONS
55	MyD88-Dependent Silencing of Transgene Expression During the Innate and Adaptive Immune Response to Helper-Dependent Adenovirus. <i>Human Gene Therapy</i> , 2010, 21, 325-336.	2.7	31
56	Oncolytic adenoviruses. <i>Oncolimmunology</i> , 2012, 1, 979-981.	4.6	31
57	Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. <i>Oncolimmunology</i> , 2018, 7, e1457596.	4.6	31
58	Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. <i>Journal of Gene Medicine</i> , 2011, 13, 253-261.	2.8	30
59	Short-term Correction of Arginase Deficiency in a Neonatal Murine Model With a Helper-dependent Adenoviral Vector. <i>Molecular Therapy</i> , 2009, 17, 1155-1163.	8.2	29
60	Metastatic state of parent cells influences the uptake and functionality of prostate cancer cellâ€derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1354645.	12.2	29
61	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. <i>Cancers</i> , 2020, 12, 1660.	3.7	29
62	Extracellular vesicles provide a capsidâ€free vector for oncolytic adenoviral DNA delivery. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1747206.	12.2	27
63	Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 459-469.	4.4	27
64	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
65	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2016, 24, 175-183.	8.2	26
66	Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus. <i>PLoS ONE</i> , 2010, 5, e13859.	2.5	25
67	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. <i>European Journal of Cancer</i> , 2010, 46, 625-635.	2.8	25
68	Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. <i>Human Gene Therapy</i> , 2012, 23, 1065-1070.	2.7	25
69	A novel<i>in silico</i>framework to improve MHC-I epitopes and break the tolerance to melanoma. <i>Oncolimmunology</i> , 2017, 6, e1319028.	4.6	25
70	Peptide Nucleic Acid-Functionalized Adenoviral Vectors Targeting G-Quadruplexes in the P1 Promoter of Bcl-2 Proto-Oncogene: A New Tool for Gene Modulation in Anticancer Therapy. <i>Bioconjugate Chemistry</i> , 2019, 30, 572-582.	3.6	25
71	Antigen-Specific Tolerance of HumanÎ±1-Antitrypsin Induced by Helper-Dependent Adenovirus. <i>Human Gene Therapy</i> , 2007, 18, 1215-1224.	2.7	24
72	GMCSFâ€armed vaccinia virus induces an antitumor immune response. <i>International Journal of Cancer</i> , 2015, 136, 1065-1072.	5.1	23

#	ARTICLE	IF	CITATIONS
73	Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16008.	4.1	23
74	Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. <i>Bioactive Materials</i> , 2022, 9, 299-315.	15.6	23
75	NOD2 Signaling Contributes to the Innate Immune Response Against Helper-Dependent Adenovirus Vectors Independently of MyD88 <i>In Vivo</i> . <i>Human Gene Therapy</i> , 2011, 22, 1071-1082.	2.7	22
76	PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice. <i>Gene Therapy</i> , 2013, 20, 1124-1130.	4.5	22
77	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 981-993.	3.4	22
78	A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. <i>ELife</i> , 2022, 11, .	6.0	21
79	Dendritic Cell Function After Gene Transfer with Adenovirus-calcium Phosphate Co-precipitates. <i>Molecular Therapy</i> , 2007, 15, 386-392.	8.2	20
80	Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. , 2022, 236, 108103.		20
81	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14008.	4.4	19
82	Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B. <i>Human Gene Therapy</i> , 2009, 20, 479-485.	2.7	18
83	Oncolytic Adenoviruses for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2517.	4.1	18
84	Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver. <i>Human Gene Therapy</i> , 2009, 20, 611-620.	2.7	17
85	In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. <i>Annals of Medicine</i> , 2011, 43, 151-163.	3.8	17
86	PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. <i>ACS Nano</i> , 2021, 15, 15992-16010.	14.6	17
87	Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	17
88	Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. <i>International Journal of Molecular Sciences</i> , 2019, 20, 621.	4.1	16
89	Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6183.	4.1	16
90	Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. <i>Cancers</i> , 2021, 13, 3408.	3.7	16

#	ARTICLE	IF	CITATIONS
91	Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 3036.	2.8	13
92	Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 193.	4.4	13
93	In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. <i>International Journal of Cancer</i> , 2014, 134, 2878-2890.	5.1	13
94	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. <i>Current Cancer Drug Targets</i> , 2018, 18, 124-138.	1.6	13
95	Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. , 2019, 7, 174.		13
96	Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 19-30.	3.1	13
97	Novel personalized cancer vaccine platform based on Bacillus Calmette-Guérin. , 2021, 9, e002707.		12
98	Discovery of a novel one-step RuO ₄ -catalysed tandem oxidative polycyclization/double spiroketalization process. Access to a new type of polyether bis-spiroketal compound displaying antitumour activity. <i>Tetrahedron</i> , 2010, 66, 9370-9378.	1.9	11
99	Influence of Cell Membrane Wrapping on the Cell-Porous Silicon Nanoparticle Interactions. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000529.	7.6	11
100	Surfaceome and Exoproteome Dynamics in Dual-Species <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> Biofilms. <i>Frontiers in Microbiology</i> , 2021, 12, 672975.	3.5	11
101	Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. <i>International Journal of Cancer</i> , 2012, 131, 253-263.	5.1	10
102	Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors. <i>Biomedicines</i> , 2013, 1, 3-16.	3.2	10
103	Î²2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection. <i>Cancer Immunology Research</i> , 2021, 9, 1354-1369.	3.4	10
104	Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice. <i>Gene Therapy</i> , 2019, 26, 121-130.	4.5	9
105	Pathogens: Our Allies against Cancer?. <i>Molecular Therapy</i> , 2021, 29, 10-12.	8.2	9
106	Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9
107	Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14006.	4.4	8
108	Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. <i>PLoS ONE</i> , 2019, 14, e0224072.	2.5	8

#	ARTICLE	IF	CITATIONS
109	GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 625-634.	4.1	8
110	Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. <i>Frontiers in Immunology</i> , 2022, 13, 826164.	4.8	8
111	Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 7550-7556.	2.4	6
112	A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 137-145.	4.4	5
113	Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. <i>Molecular Pharmaceutics</i> , 2011, 8, 93-103.	4.6	4
114	661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model. <i>Molecular Therapy</i> , 2016, 24, S262.	8.2	3
115	Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform. , 2015, 3, .		2
116	Viral Nanoparticles: Cancer Vaccines and Immune Modulators. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 317-325.	1.6	2
117	Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5. <i>PLoS ONE</i> , 2010, 5, e13103.	2.5	2
118	71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice. <i>Molecular Therapy</i> , 2015, 23, S31.	8.2	1
119	408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma. <i>Molecular Therapy</i> , 2016, 24, S161-S162.	8.2	1
120	Abstract A034: Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma. , 2016, , .		1
121	220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice. <i>Molecular Therapy</i> , 2015, 23, S86-S87.	8.2	0
122	622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy. <i>Molecular Therapy</i> , 2015, 23, S247.	8.2	0
123	665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102. <i>Molecular Therapy</i> , 2015, 23, S264-S265.	8.2	0
124	Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines. <i>Annals of Oncology</i> , 2016, 27, viii2.	1.2	0
125	659. Oncolytic Adenovirus Loaded with Bioactive Modified Peptide as a Novel Approach to Treat Cancer. <i>Molecular Therapy</i> , 2016, 24, S261.	8.2	0
126	642. Oncolytic Vaccines with Modified Tumor Epitopes for Cancer Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, S254.	8.2	0

#	ARTICLE	IF	CITATIONS
127	Enhanced anti-cancer vaccines with a new epitope improvement system. <i>Annals of Oncology</i> , 2016, 27, viii2.	1.2	0
128	Homology between cancer and viral epitopes as criteria to design improved cancer vaccines. <i>Annals of Oncology</i> , 2017, 28, xi18.	1.2	0
129	Abstract 1488: Viral molecular mimicry influences the antitumor immune response in murine and human melanoma. , 2021, , .		0
130	Abstract 1897: PeptiCHIP: A novel microfluidic-based chip platform for tumor antigen landscape identification. , 2021, , .		0
131	Abstract 1867: Characterization in patient derived tumor organoids of novel oncolytic adenoviruses expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitors. , 2021, , .		0
132	CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13035-e13035.	1.6	0
133	Abstract 3304: Oncolytic adenovirus with low-dose temozolomide induces autophagy and antitumor immune responses preclinically and in cancer patients.. , 2013, , .		0
134	Oncolytic Viruses for Treatment of Cancer. , 2015, , 185-200.		0
135	Abstract B51: Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. , 2015, , .		0
136	Abstract B123: Local treatment with PeptiCRAd-1, a novel cancer immunotherapy approach, mediates a systemic antitumour CD8+ T-cell response and infiltration of CD8+ and CD4+ T-cells into distant untreated tumors in a clinically relevant humanized mouse melanoma model. , 2019, , .		0
137	Oncolytic viruses for antigen delivery. , 2022, , 1-19.		0